Navigation Links
Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
Date:11/11/2013

temprop="name">Susan McElroy, MD; Research Institute, Lindner Center of HOPE, Mason, OH, USA.
Title: Naltrexone/bupropion is associated with early and longer-term improvement in binge eating disorder that is related to improvement in depression

About Contrave
About Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) being evaluated for the treatment of obesity: In 2012, Orexigen enrolled more than 10,400 with approximately 8900 randomized patients in the Light Study. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), is to assess the occurrence of major adverse cardiovascular events in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug Application to the FDA by year end.

In October, Orexigen submitted a Marketing Authorization Application for Contrave to the European Medicines Agency.

Orexigen has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a NDA has been submitted and reviewed by the FDA. The company has also reached agreement with the FDA on a SPA for the Light Study, the Contrave cardiovascular outcomes trial. The company's other product candidate, Empatic, has completed Phase 2 clinical t
'/>"/>

SOURCE Orexigen Therapeutics, Inc.; Takeda Pharmaceuticals, U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Hospira, Inc. (NYSE: HSP ), the ... technologies, today reported results for the second quarter ... quarter were $1.1 billion and adjusted* diluted earnings ... items as described later in this press release ... Accepted Accounting Principles (GAAP) basis, second-quarter 2014 diluted ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... 30. Juli 2014 Die Apex ... Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, gibt ... München in Deutschland anfechten werden. Dieses hat ... ein Patent von ResMed verletze. Apex weist ... Ländern gegen verschiedene Patente von ResMed Anfechtungen ...
Breaking Medicine Technology:Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Sept. 23 Surefil, a contract manufacturer of liquid-fill ... medical industries, and energy drinks, emerged from Chapter 11 ... The company was able to attract ABACO Partners, LLC ... Executive Officer of Universal Forest Products, Bill Currie, to ...
... Netherlands, Sept. 23 DuPont (NYSE: DD ... form a joint venture to develop, manufacture and commercialize ... The joint venture will be named Actamax Surgical Materials ... will each share a 50 percent interest. The ...
Cached Medicine Technology:Surefil Emerges from Chapter 11 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 3DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 4
(Date:7/30/2014)... elderly American adults is being financially exploited often ... crisis especially affects poor and black people. It merits ... citizen who cares about the dignity and well-being of ... Medical College in the US. She led one of ... findings of which appear in the Journal of ...
(Date:7/30/2014)... hospital in Ireland has shown than many of them did ... the risk of entrapment. The report, published online in the ... for careful selection of patients for whom bedrails are to ... maintenance of hospital bed systems. , Bedrails are commonly used ... although the risk for any individual is extremely low, people ...
(Date:7/30/2014)... The report entitled “Global Pulse Oximetry Market: Trends ... dynamics and changing trends in the global pulse oximetry ... sizing of the global pulse oximetry market and also ... same. It further captures the global market share based ... Further, the report discusses the domestic market of United ...
(Date:7/30/2014)... Los Angeles cosmetic dentist , ... that can help patients create their dream smiles at ... gums form the foundation of smile confidence, but cosmetic ... misshapen teeth or stains may not interfere with dental ... The right cosmetic treatments can eliminate chips, erase stains ...
(Date:7/30/2014)... July 30, 2014 Building ENT and ... allergy, and audiology practice in Westchester County takes the ... technology, a superb underlying corporate structure and protocols, and ... also takes a leading Chief Financial Officer to help ... (WCBJ), that’s exactly what it possesses. In fact, in ...
Breaking Medicine News(10 mins):Health News:Older adults are at risk of financial abuse 2Health News:High frequency of potential entrapment gaps in hospital beds 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 2Health News:The Leading Ear, Nose, and Throat Practice in Westchester County Has One of the Leading CFO’s in Westchester County! 3
... BAYFIELD, Colo., July 14 Kanakuk Colorado today released the ... illness. , , "Yesterday, Kanakuk ... that at 2:00 p.m. on Saturday afternoon 2 campers presented to ... throats. Within 30 minutes these campers had been isolated from the ...
... , , , ... an older adult can easily turn into a downward slide into a ... health care for the elderly, Aurora Health Care is sponsoring a continuing ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) , ...
... BINGHAM FARMS, Mich., July 14 United Physicians ... 1st, 2009. The decision to take a more eco-friendly ... faxes that have historically been used to communicate with the ... "The decision to ,Go Green, with our business communications ...
... HAYWARD, Calif., July 14 Solta Medical, Inc. (Nasdaq: ... today announced that it will release its financial results for the ... Thursday, July 30, 2009. The Company will also host a ... p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results ...
... MIAMI and SAN DIEGO, July 14 Sorrento ... for the generation of fully human monoclonal antibodies, and QuikByte ... no active operations, have signed a merger agreement pursuant to ... QuikByte. After the merger is completed, QuikByte will be ...
... compliance, study finds , TUESDAY, July 14 (HealthDay News) -- ... use of a reminder program for women who were due ... Permanente staff checked electronic health records of its 35,000 members ... a mammogram for 20 months. They were sent a postcard ...
Cached Medicine News:Health News:Statement for Attribution to Andy Braner, President, Kanakuk Colorado, Bayfield CO 2Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 2Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 3Health News:Aurora Health Care Sponsors Education Event to Improve Care for the Elderly 4Health News:United Physicians Goes Green Effective August 1st, 2009 2Health News:Solta Medical, Inc. Announces Second Quarter 2009 Results Release Date and Conference Call 2Health News:QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement 2Health News:QuikByte Software, Inc. and Sorrento Therapeutics, Inc. Announce Merger Agreement 3Health News:Reminders Boost Mammography Appointments 2
... bench style refrigerator (can be situated on or ... of bags is to be stored as in ... white colorbond steel while the interior is a ... door is key lockable. Control panel is flush ...
The Testosterone Enzyme Immunoassay is intended for the quantitative determination of Testosterone concentration in human serum. No special pretreatment of the sample is necessary. For in vitro Diag...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... This HPLC for Vitamin B6 makes ... an easy, fast and precise method. The ... form for preparation and separation of the ... of HPLC analytics is the simultaneous handling ...
Medicine Products: